$10.01
-0.12 (-1.18%)
Open$10.21
Previous Close$10.13
Day High$10.70
Day Low$9.73
52W High$15.74
52W Low$2.69
Volume—
Avg Volume31.5K
Market Cap36.07M
P/E Ratio—
EPS$-21.58
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+252.1% upside
Current
$10.01
$10.01
Target
$35.25
$35.25
$27.20
$35.25 avg
$53.45
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.98M | 7.00M | 7.72M |
| Net Income | -1,326,181 | -1,545,557 | -1,571,652 |
| Profit Margin | -19.0% | -22.1% | -20.4% |
| EBITDA | -1,878,590 | -1,945,549 | -2,406,257 |
| Free Cash Flow | -1,092,947 | -1,597,568 | -1,077,092 |
| Rev Growth | +10.9% | +1.3% | +2.5% |
| Debt/Equity | 0.21 | 0.18 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |